Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Big Short - SCAM alert- The heat cap is at best as good as CHEMO!! IMO
Anyone else think this thing is a high level scam. I don’t think they have one 5 yr survivor
Did the CEO dump virtually his entire position? WTF is that about
You got that Absolutely right norisknorewards..
NVCR ends is closer than what that dude wishes not to be...
The device is no better than CHEMO!!
Easiest short he said
FDA Cleared CHEMO as well just incase... And that has miserably failed///
There is absolutely NO CURE in NoVoCure!!
Best Short EVER IMO
This below statement from their PR confirms that fact!!
".....which has the Potential to meaningfully extend patient survival beyond what was previously possible.,& that says it all. |the Potential .. to extend ..Survival" ... Its all that she wrote~~~~
Could be this am conference today?
Novocure plans to release the full results of the LUNAR study at a future medical conference. Novocure expects to file a Premarket Approval application with the U.S. Food and Drug Administration (FDA) in the second half of 2023. Novocure also expects to file for a CE Mark in the European Union concurrently with the FDA submission.
“We are pleased with the positive readout of the LUNAR study. Prior to LUNAR, the last phase 3 trial to lead to significant improvement in overall survival in late-stage, platinum-resistant non-small cell lung cancer was six years ago, underlining the difficulty in treating this disease,” said William Doyle, Novocure’s Executive Chairman. “We are also pleased by the profound performance of the TTFields together with immunotherapy, which has the potential to meaningfully extend patient survival beyond what was previously possible. I would like to thank our patients and investigators for their courage and dedication in completing LUNAR. And, I would like to thank Novocure’s employees for their unrelenting commitment to patients and their perseverance in propelling Novocure to this major milestone.”
“We are excited about the potential of TTFields to address the unmet medical needs of lung cancer patients around the world. In China, lung cancer is the most common cancer type with approximately 700,000 new NSCLC cases diagnosed each year,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are pleased to contribute and be a part of the LUNAR study and this partnership is yet another great example of how collaboration benefits everyone.”
Novocure plans to release the full results of the LUNAR study at a future medical conference. Novocure expects to file a Premarket Approval application with the U.S. Food and Drug Administration (FDA) in the second half of 2023. Novocure also expects to file for a CE Mark in the European Union concurrently with the FDA submission.
I penny pumper writing a narrative that's about to get burnt. Fda clearance is huge!!
NVCR microwave device hype will not last and rapidly fading!!
Those who understand how it works know that its application is at best comparable to chemo in terms of effectiveness & the real life experiences of the prescribing doctors & their cancer patients has been increasingly confirming that!!
Why do you think with a bloated $10B market cap, its earnings are non-existence and dropping??
Comparatively speaking, Chemo kills the cancer as well as the normal cells..
And the helmet, based on it claim mode of action of interfering with replication of fast dividing cells, such as cancer cells, inhibit the division of those cells at the site where the microwaves are targeting. Obviously elsewhere in the body, the cancer cells lives happily and keep invading..
Now consider the fact that activated immune system effector cells, such as the T-cells, are also fast dividing. Meaning that the microwaves also inhibit division of the activated immune cells thus, inhibiting the division of the activated immune cells that might have been estimated in some ways. A defeated claim for immune cell activation!!
So the microwaves Inhibit not only cancer cells replication, but also, activated immune cell replication IMO..
And IMO, the lack of interest of the medical community based on the real life experience of their patients as well as their poor quality of their remaining life at massive cost to them are all supportive of that view!!
A new & innovative alternative that stimulate the totality of the naturally occurring immune system from within is urgently needed!!
LOL -- I tried to short this a couple of time. Got my ass kicked.
$NVCR: You said it....... ust hit $185 in PreMarket
WOW.................. whatta MONSTER move.
GO $NVCR
How many shares of NVCR will be sold over the next few weeks by management?
Not that I'm aware of. Over the last five months or so a number of institutional buying has happened.
Why are the insiders selling? Is something going on?
AACR:
387 / 23 - Blood brain barrier (BBB) disruption by tumor treating fields (TTFields) in a human 3D in vitro model https://www.abstractsonline.com/pp8/#!/10517/presentation/12182
1305 / 15 - Tumor Treating Fields (TTFields) promote a pro-inflammatory phenotype in macrophages https://www.abstractsonline.com/pp8/#!/10517/presentation/16885
1801 / 30 - Application of Tumor Treating Fields (TTFields) to cancer cells enhances their membrane permeability https://www.abstractsonline.com/pp8/#!/10517/presentation/20545
1866 / 11 - Transcriptomics analysis for identification of pathways involved in the response to Tumor Treating Fields (TTFields) https://www.abstractsonline.com/pp8/#!/10517/presentation/16328
2037 / 15 - Spatial omic changes of malignant pleural mesothelioma following treatment using tumor-treating fields https://www.abstractsonline.com/pp8/#!/10517/presentation/12731
2601 / 14 - Concomitant treatment of ovarian cell lines with Tumor Treating Fields (TTFields) and PARP inhibitors https://www.abstractsonline.com/pp8/#!/10517/presentation/12967
2659 / 2 - Inhibition of PI3K sensitized cancer cells to Tumor Treating Fields (TTFields) https://www.abstractsonline.com/pp8/#!/10517/presentation/15079
3156 / 7 - Tumor Treating Fields reduce cellular survival of human mesenchymal stromal cells via apoptosis and senescence induction https://www.abstractsonline.com/pp8/#!/10517/presentation/14670
3252 / 21 - Tumor treating fields suppression of ciliogenesis enhances temozolomide toxicity https://www.abstractsonline.com/pp8/#!/10517/presentation/16105
3447 / 5 - Tumor treating fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord https://www.abstractsonline.com/pp8/#!/10517/presentation/12120
3450 / 8 - Impact of model inaccuracy on dose estimation in TTFields therapy https://www.abstractsonline.com/pp8/#!/10517/presentation/12124
3465 / 23 - Efficacy of concomitant application of Tumor Treating Fields (TTFields), temozolomide and lomustine in glioblastoma cancer cells in vitro https://www.abstractsonline.com/pp8/#!/10517/presentation/18151
CT234 / 5 - PANOVA-3: A phase 3 study of tumor treating fields with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma https://www.abstractsonline.com/pp8/#!/10517/presentation/20361
The IDMC has recommended that the PhIII trial in ovarian should continue following an interim analysis. The analysis showed that an increase in sample size is not necessary and the committee recommended that the trial continue to a final analysis.
The primary endpoint of INNOVATE-3, which is examining TTFs in combination with paclitaxel for platinum-resistant ovarian, is OS. Secondary endpoints include PFS, ORR, and severity and frequency of AEs.
Insiders keep dumping.
This thing is a pig
Aren't you aware that NVCR is running five pivotal trials (brain mets from NSCLC, NSCLC, rGBM, ovarian and pancreatic) that will readout in the next few years? As for NWBO, I very much doubt we will ever see data from them, or it will be utter bull.
LOL. NWBO is toast and everybody knows it. They are morphing into a CDMO that will be worth a few hundred million.
NVCR will live or die by the lung cancer trial. If that fails they can continue to eak out an existence, but no real upside. If it works, they can say bye-bye to tiny markets like GBM.
NWBO successful trial will crush this stock, yall heard it from me first. I see you Ex, i see you...
NVCR is going to be a trading stock for a while. I do not see any likely positive/negative drivers within the next year.
There is the IA in the ovarian trial in the next month or two. But that is so early that it is 90% to be the blah "trials continues as planned".
I doubt any real excitement on the operation/financial side. Hopefully a bit more uptick than the last set of numbers.
So, play your charts to your hearts content
Getting interesting $NVCR, how far below 200dma will it go? GLTA
Watching $NVCR closely, looking to get back in real soon! GLTA
So what exactly does the news mean?
I have never heard of a DSMB recommending that the trial stop enrollment and add a 12 month follow-up window to keep the same power.
In the proper sense, all keeping the same power means is that they expect the same number of events. If so, this could be no more that NVCR saw that enrollment was so slow they might as well just wait the 12 months than keep trying to enroll.
In the best sense, the DSMB sees the curves separating so well that they know they have sufficient patients and only need time to collect AEs.
In the worst case, the DSMB just called for a futility halt and NVCR is spinning it. In the cases where a futility halt happens before enrollment is complete. the trial can continue but it is unethical to enroll more patients. An that does match what just happened.
Excellent news; nice upside run. More tutes increasing their position this afternoon.
Agreed - Book Value Per Share $4.66
Pretty big price difference... imo
I'm donating the 1000 shares of NVCR to charity, just as I did with my NWBO shares last year. GLTA
Wow, what a pre-market move! Been holding 1000 shares that I purchased after reading about NVCR over on the NWBO message board last year. Might be a good day to sell! GLTA
ae kusterer Tuesday, 01/05/21 09:54:28 AM
Re: None 0
Post #
344899
of 344909
IS THE OPTUNE 5 YEAR SURVIVAL RATE 29%?Please post that data/ or scientifuc journal.
"The company's product is currently sold for the treatment of glioblastoma, or cancer of the brain. "About 29% of the patients that manage to persist with the treatment survive for five years after treatment starts, which compares with 4-5% who survived for five years from the date of diagnosis before our product reached the market. This product has demonstrably changed the outcome of this aggressive disease," says Danziger"
Basin Street Blues Member Level Tuesday, 01/05/21 08:54:29 AM
Re: None 0
Post #
344883
of 344898
"One day every cancer patient will use our product"
Asaf Danziger
30 Dec, 2020 15:23
Gali Weinreb
NovoCure's innovative cancer treatment has already made it the third most valuable Israeli company on Wall Street. CEO Asaf Danziger talks to "Globes".
At the beginning of November, "Globes" reported that NovoCure (Nasdaq: NVCR), developer of a medical treatment for cancer, was worth $12 billion, and that it had surpassed Teva's market cap. Between the end of November and now, the company's market cap rose by a further 30%, to $17 billion. NovoCure has more than doubled its value in a year.
NovoCure's market cap makes it the third most valuable Israeli company traded on Wall Street, after Check Point Software Technologies Ltd. (Nasdaq: CHKP) and NICE Systems Ltd. (Nasdaq: NICE; TASE: NICE). Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), once the undisputed leader among Israeli companies, is currently only tenth, and long-established Israeli-American company Perrigo is worth only a third of the value of NovoCure. Amid dozens of failures of Israeli healthcare companies on their way to the stock market, NovoCure shows what heights this sector can reach.
Asaf Danziger, who has been NovoCure's CEO almost since its inception two decades ago, seems a little embarrassed when asked to comment directly on these figures. "Market cap is very nice, but it's not the main thing as far as we're concerned," he says in a rare interview with "Globes". "Certainly when you look at the comparison with a company like Teva, which has sales of more than $1 billion a quarter and touches so many people," he adds.
NovoCure does not yet have Teva's numbers. In the first nine months of 2020, it had revenue of $350 million, 38% more than in the corresponding period of 2019. This revenue is based on 3,300 active patients at the end of the period, who made a monthly payment for the treatment. This looks like a very small number of patients, in comparison with the company's market potential in the type of cancer it treats, and even smaller in comparison with the range of types of cancer it could treat in the future.
The company's product is currently sold for the treatment of glioblastoma, or cancer of the brain. "About 29% of the patients that manage to persist with the treatment survive for five years after treatment starts, which compares with 4-5% who survived for five years from the date of diagnosis before our product reached the market. This product has demonstrably changed the outcome of this aggressive disease," says Danziger.
RELATED ARTICLES
NovoCure Photo: Nasdaq
Market cap of Israel-founded Novocure exceeds $9b
Novocure uses electrodes to treat brain tumors
Anchiano Therapeutics jumps after Chemomab merger
Cancer drug development co Biosight raises $46m
BiolineRX soars on positive Phase 3 blood cancer trial results
The product is approved for marketing for the treatment of glioblastoma in the US, Japan, China, and in several European countries, as well as in Israel. It is covered by private and state health insurance in all these countries. It became part of the Israeli "health basket" in 2020.
This year, the product was approved for the treatment of mesothelioma, a rare lung cancer caused by asbestos. The success in clinical trials and in obtaining approval for this indication demonstrated that the company's technological concept would work for conditions besides brain cancer, and that theoretically it could be effective in treating many cancer types. The company is currently in the midst of a Phase III trial - the final stage before product approval - for difficult-to-treat types of cancer, such as cancer of the pancreas, the ovaries, the lung, and metastases in the brain from lung cancer.
Asked about the company's future, Danziger responds cautiously, "If you look at the types of cancer for which our product is undergoing trials, metastases of lung cancer in the brain, for example, is a market ten times bigger than glioblastoma." In other words, if these trials succeed like the trials for glioblastoma, the market potential could grow substantially.
"When we came to making an offering on Nasdaq in 2015," Danziger says, "we came with the first FDA approval in hand, and within a month we had another approval. In other words, we told the market 'we only have execution risk.' And indeed, we floated the company at a valuation of nearly $2 billion. As far as I know, only three biotech companies have reached the stock exchange with a valuation like that."
The IPO in 2015 actually closed at a price lower than was sought, because of market conditions, and the stock even declined at first. Thanks to the low pricing at the outset, those who invested in the IPO eventually made such a dream return. "We promised at the time of the IPO that the product would be in daily use and that the insurance companies would pay for it, and we kept our promise. To make a promise and fulfill it is apparently something not very common."
Why have you not been sold by now? Cancer treatment companies have been sold at much earlier stages.
"AS CEO of a public company I have almost no control over the question whether we will be sold."
The technology: Electric fields that reach the growth
NovoCure's technology is basically a completely new approach to treating cancer, developed by Prof. Yoram Palti, now aged 82, professor emeritus of physiology and biophysics at the Technion-Israel Institute of Technology. It consists of electric fields directed at the growth from several directions that disrupt the growth of the cancerous cells, without damaging other areas. The treatment is akin to radiation, but without the damage done by radiation to tissues that it encounters on the way to the growth.
"No-one believed in this idea at first," says Danziger. "They told him (Palti) that his ideas were fundamentally untenable. Today, he continues to develop and create and invent like ten doctoral students."
Palti has related in the past how he received the initial money for financing the company, some $300,000, from a friend called Lennart Perlhagen, formerly a senior manager at European pharmaceuticals companies Meda AB and Pharmitalia. Perlhagen served as a director of NovoCure until 2018, and the value of his personal holding in the company is in the hundreds of millions of dollars, as is that of Palti.
Danziger was in effect the company's first CEO, and he even let his brain be used in its initial trials, as did all the managers - so Palti has said in the past.
When the company reached proof of concept, it immediately began to attract international interest. William Doyle, who had management experience in global medical devices companies, invested in the company at the outset, and he serves as its chairman to this day.
The model: Fixed monthly payment from patients
The disadvantage of the company's product at present is a degree of discomfort in using it. It does not cause the severe side effects of radiation or chemotherapy. However, in order to use the company's device for brain cancer, for example, the hair must be shaved off and electrodes must be attached to the head, and the machine that produces the electric fields has to be carried around everywhere.
You said that the product is effective in 29% of the people who manage to persist in the treatment. Are there people who do not manage to persist?
"The treatment extends the lives even of patients who are not completely strict about using the device. In the company's early days, fears were expressed that patients would not use the product, and that women would not agree to shave their hair. Sick people want to live. We have had a very good response to the treatment, and the device is much more convenient than in the past. Use of the treatment is steadily growing in time around the world. After all, we receive payment every month, and our revenue is rising as patients use the treatment and live longer."
In treating lung cancer there is no need to shave the head and the device is not visible. It still has to be used for most hours of the day. This product does not yet have insurance cover, but the company has already started to sell it to patients. "From an ethical point of view, our approach is that as soon as we have an approved product, we start marketing it to patients, and the insurance cover will come later. This is not a strategy for expediting cover - what interests the insurance companies is the trial results, and not if you are pleasant or ask nicely. It simply seems to us the right thing to do for the patients."
How has the coronavirus pandemic affected you?
"In February, we went into 'coronavirus mode'. We appointed a VP for coronavirus who is also a doctor, and by the end of February our team was protected as very few hospitals in the world are protected. No patient of ours anywhere in the world missed a minute of treatment because of the coronavirus. We launched a digital product that passed FDA approval, in order to enable patients to download data from the device and send them to their doctors or to us. We continued to recruit patients for our trials and we continued to grow.
"For a long time now, we have allowed working from home. Beyond that, it has been business as usual. We help our employees as much as possible, whether it's a psychologist or a babysitter - in the US there's even a 'Zoom-sitter', someone whose job it is to sit with the children on Zoom and make sure that they are succeeding in studying remotely. Our employees are very important to us. Our staff turnover is orders of magnitude lower than the norm in the industry."
Are you bringing about a revolution in cancer that could be as big as immunotherapy?
"Why compare? Revolution is a word that the media love to use, and we deal in science and medicine. I can say that we are introducing a new kind of therapy, like radiation, like chemotherapy, and I believe that one day there won't be a single cancer patient who isn’t treated with electric fields."
And you have exclusivity on that?
"We're patent protected for decades ahead."
Are you an Israeli company?
"We have never been registered in Israel. We have a thousand employees around the world, after growing substantially during the coronavirus pandemic, and 200 of them are in Israel. In addition, our only research and development center is located in Israel, and production takes place in Israel, in close collaboration with AL Electronics."
Published by Globes, Israel business news - en.globes.co.il - on December 30, 2020
InvestorsHub NewsWire
PAOG Engages Veristat For CRO Services To Advance CBD COPD Treatment • PAOG • Jan 5, 2021 10:23 AM
WSGF Targets $100 Million In Revenue Opening Real Estate Investment Market To Smaller Investors • WSGF • Jan 5, 2021 10:01 AM
InvestorsHub NewsWire
PAOG Engages Veristat For CRO Services To Advance CBD COPD Treatment • PAOG • Jan 5, 2021 10:23 AM
WSGF Targets $100 Million In Revenue Opening Real Estate Investment Market To Smaller Investors • WSGF • Jan 5, 2021 10:01 AM
Splash Beverage Group Inc. Announces "The Big Biz Show" Live Interview with CEO Robert Nistico • SBEV • Jan 5, 2021 9:39 AM
PSYC Announces Formation of Advisory Board • PSYC • Jan 5, 2021 9:30 AM
Ideanomics Signs a Definitive Agreement to Acquire Utah-based Wireless Charging Provider WAVE • IDEX • Jan 5, 2021 8:03 AM
UP LIKE A ROCKET, DOWN LIKE A ROCK? - Tesla (TSLA) with Clem Chambers • TSLA • Jan 4, 2021 4:45 PM
4 OTC Stocks on the Move: CELZ DSGT IQST PMPG • IQST • Jan 4, 2021 10:23 AM
Pennexx Has Completed All Necessary Approvals and Agreements to Release its Mastercard™ Your Social Offers Prepaid Debi... • PNNX • Jan 4, 2021 10:10 AM
Kona Gold Beverage, Inc. Announces Effectiveness of Form S-1 Registration Statement • KGKG • Jan 4, 2021 10:00 AM
NexTech Increases It's Treasury Bitcoin Holdings to $4million • NEXCF • Jan 4, 2021 9:30 AM
4CABLE TV INTERNATIONAL, INC. ANNOUNCES ACQUISITION OF HEALTHCARE AND WELLNESS CLINICS OF AMERICA and CORPORATION CLINIC • CATV • Jan 4, 2021 9:00 AM
Start posting your company's news. Only $200 per official company press release!
Public Reply | Private Reply | Keep | Last Read Post New Msg Next 10 | Previous | Next
Follow Board Follow Board
Follow User
Ignore User
Keyboard Shortcuts
Report TOS Violation
© 2021 InvestorsHub.com, Inc.
About
About Us
Terms of Service
Cookie and Privacy Policy
Advertise With Us
Data Accreditations
Disclaimer
Help
FAQ
Handbook
Q&A Forum
Contact Us
Educational
Market Vision (YouTube)
Educational Channel
Stock Market 101
Investor Help Forum
More
Corporate Solutions
iHub on Facebook
iHub on Twitter
iHub iPhone/iPad App
iHub Android App
iHub NewsWire
You are ae kusterer on WEB9
Consent Preferences
I am wondering why this stock dropped so much today?
LOL... a bit of a stretch.
Funny NVCR folks don’t talk about NWBO at all. NWBO board talks about you all day..
I never posted here before, and I humbly admit that I haven't read the posts here, but I posted this on the NWBO board, where I've been following the co since early 2013:
''(And 19% loss at the end of day.)
I hope they come join up NWBO with no toxicities and no helmet, and with prolonged survival, and a long tail... and the next soc!''
Lots of money to be made if the phase III is positive, which I believe will be, imo. GL
Just if some people are interested, I learn a lot from Doc Logic, Flipper, Sentiment_Stocks, Longfellow95, Marzan, and many more.
And read Exwannabe, HappyLibrarian, Learningcurve2020, etc if you want to be told bs from none investors...
https://finance.yahoo.com/video/using-electric-fields-fight-cancer-181659054.html?soc_src=social-sh&soc_trk=tw
that is a Yahoo link that contains a partial interview with the current Chief Executive of NVCR. They lost the signal about 3/4 of way into the interview. The CEO stated...that the GB is only the beginning...the term he used I believe was "just the tip of the iceberg." He mentioned the other pipleline items and emphasized pancreatic cancer treatments in particular. Best to all the longs.
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
559
|
Created
|
10/07/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |